Omeros negotiates $60 million at-the-market issuance sales agreement

Offering will be conducted by agent MLV, company reports in 8-K filing

By Devika Patel

Knoxville, Tenn., Dec. 14 - Omeros Corp. arranged a $60 million at-the-market issuance sales agreement with MLV & Co. LLC on Dec. 14, according to an 8-K and prospectus supplement filed Friday with the Securities and Exchange Commission.

Proceeds will be used for general corporate purposes, including clinical development and potential commercialization of OMS302 and OMS103HP, as well as research and development, preclinical studies, clinical trials, capital expenditures, working capital and advancing potential products towards commercialization.

Omeros is a biopharmaceutical company based in Seattle.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.